MolMed now part of AGC Biologics
Biotechnology Research • 
Segrate, Lombardy, Italy • 21-50 Employees
Company overview
| Headquarters | via Olgettina 58, San Raffaele Biomedical Science Park (DIBIT), Milano, Lombardia 20132, IT |
| Phone number | +393902212771 |
| Websites | |
| NAICS | 541714 |
| SIC | 271 |
| Keywords | Car-T Cells, Cell & Gene Therapies, Gmp Cell & Gene Manufacturing |
| Founded | 1996 |
| Employees | 21-50 |
| Socials |
Key Contacts at MolMed now part of AGC Biologics
Antonio Lambiase
Clinical Director
Daniele Pieraccioli
Director, Intellectual Property
Salvatore Toma
Director Drug Development & Production
MolMed now part of AGC Biologics Email Formats
MolMed now part of AGC Biologics uses 1 email format. The most common is {first name}{last name} (e.g., johndoe@agcbio.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@agcbio.com | 100% |
About MolMed now part of AGC Biologics
MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in both clinical and preclinical development, both autologous and allogeneic. Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis®, that received orphan drug designation, is currently in Phase III, but has already obtained a Conditional Marketing Authorization by the EU Commission in the 2nd half of 2016 as well as reimbursement conditions in Italy and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, MolMed is developing a new therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic; the most advanced product, CAR-T CD44v6, received in March 2019 the authorization to start human clinical trials in onco-hematologic indications (AML and MM) , following an extensive pre-clinical phase; the product is potentially effective also in several epithelial solid tumors. With regards to allogeneic CARs, MolMed is developing a pipeline based on NK (Natural Killer) cells, following a research agreement signed in 2018 with Glycostem. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis) as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. MolMed is listed on the MTA of Borsa Italiana since 2008.
MolMed now part of AGC Biologics revenue & valuation
| Annual revenue | $41,800,000 |
| Revenue per employee | $909,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $133,700,000 |
| Total funding | $16,700,000 |
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
MolMed now part of AGC Biologics has 21 employees across 6 departments.
Departments
Number of employees
Funding Data
Explore MolMed now part of AGC Biologics's funding history, including investment rounds, total capital raised, and key backers.
United States
Türkiye
United Kingdom
Netherlands
Australia
Slovakia
Frequently asked questions
4.8
40,000 users
